treatment with REC-994 400 mg showed promising signals in both MRI-based lesion volume reduction and functional outcome as ...
Showed promising signals of efficacy in MRI-based lesion volume reduction and functional outcomes measured by changes in the modified Rankin scale (mRS) in patients receiving REC-994 400 mg.
Revalesio updates new analyses from phase 2 RESCUE clinical study of RNS60 in patients with acute ischemic stroke: Tacoma, Washington Friday, February 7, 2025, 18:00 Hrs [IST] Rev ...
The following is a summary of “Endovascular Thrombectomy for Extracranial Internal Carotid Artery Occlusions With Large ...
In any case, there was no mortality signal associated with alteplase administered up to 24 hours after a stroke in HOPE.
In an editorial, J. Mocco, MD, of Mount Sinai Health System in New York City, characterized the DISTAL and ESCAPE-MeVO ...
Met primary endpoint of safety and tolerability in CCM patients with no treatment-related discontinuations or Grade 3 adverse eventsIn comparison to placebo, treatment with REC-994 400 mg showed promi ...
Use of endovascular thrombectomy in patients with acute ischemic stroke caused by occlusions in distal vessels has failed to ...
Three trials showed no improvement in functional outcomes, and the potential for harm, versus medical therapy alone.
In patients with high comorbidity burden that receive EVT for MCA medium-vessel occlusion there are worse clinical outcomes.
Secondary outcomes were door-to-needle time, neurological deficits (assessed using the National Institutes of Health Stroke Scale [NIHSS ... (measured using the modified Rankin Scale [mRS ...
The results increase “my confidence that this approach has merit,” Lauren Sansing says. More trials are on the way.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback